Phosphodiesterase (PDE)
Phosphodiesterase (PDE) is any enzyme that breaks a phosphodiester bond. Usually, people speaking of phosphodiesterase are referring to cyclic nucleotide phosphodiesterases, which have great clinical significance and are described below. However, there are many other families of phosphodiesterases, including phospholipases C and D, autotaxin, sphingomyelin phosphodiesterase, DNases, RNases, and restriction endonucleases, as well as numerous less-well-characterized small-molecule phosphodiesterases. The cyclic nucleotide phosphodiesterases comprise a group of enzymes that degrade the phosphodiester bond in the second messenger molecules cAMP and cGMP. They regulate the localization, duration, and amplitude of cyclic nucleotide signaling within subcellular domains. PDEs are therefore important regulators ofsignal transduction mediated by these second messenger molecules.
Phosphodiesterase (PDE) Isoform Specific Products
-
Phosphodiesterase (PDE)
(553)
View all products
-
PDE1
(60)
View all products
-
PDE2
(51)
View all products
-
PDE3
(93)
View all products
-
PDE4
(198)
View all products
-
PDE5
(97)
View all products
-
PDE6
(22)
View all products
-
PDE7
(28)
View all products
-
PDE9
(19)
View all products
-
PDE10
(53)
View all products
-
PDE11
(13)
View all products
-
PDE12
(2)
View all products
-
PDE8
(11)
View all products
-
Autotaxin
(36)
View all products
All Product Categories
-
Phosphodiesterase (PDE) Inhibitors
(915)
View all products
-
Phosphodiesterase (PDE) Agonists
(3)
View all products
-
Phosphodiesterase (PDE) Antagonists
(3)
View all products
-
Phosphodiesterase (PDE) Activators
(7)
View all products
-
Phosphodiesterase (PDE) Modulators
(8)
View all products
-
Phosphodiesterase (PDE) Degraders
(4)
View all products
-
Phosphodiesterase (PDE) Controls
(8)
View all products
-
Phosphodiesterase (PDE) Substrates
(4)
View all products
-
Phosphodiesterase (PDE) Ligand
(1)
View all products
-
Phosphodiesterase (PDE) Related Products (1009)
Related Products (1009)
-
Antibodies (4)
-
Phosphodiesterase (PDE) Isoform Comparison
-
PF-04827736
0 ImagesCat. No.: HY-120195ACAS No.: 2230054-75-6PF-04827736 (compound (S)-3) is a selective PDE1 inhibitor with IC50 values of 9.1 nM, 38 nM and 42 nM for PDE1B, PDE1C and PDE1A. PF-04827736 selectively inhibits human PDE1 over the other 10 superfamily members (PDE2-PDE11). PF-04827736 can be used for the study of cardiovascular disease.
-
Hoquizil hydrochloride
0 ImagesCat. No.: HY-118938CAS No.: 23256-28-2Hoquizil hydrochloride is a novel bronchodilator with oral activity, demonstrating phosphodiesterase inhibitory effects and potential for modulation of smooth muscle contraction.
-
PDE5-IN-1
0 ImagesCat. No.: HY-103084CAS No.: 2109805-65-2PDE5-IN-1 is an orally active, selective PDE5 inhibitor with an IC50 of 5.6 nM. PDE5-IN-1 forms hydrogen bond interactions with the Q817 residue in the catalytic domain of PDE5, and aromatic π-π stacking interactions with the F820 residue. PDE5-IN-1 exerts anti-cardiac hypertrophy and vasodilatory effects, reduces mean pulmonary arterial pressure and right ventricular hypertrophy index. PDE5-IN-1 can be used in the research of pulmonary arterial hypertension.
-
Sequosempervirin B
0 ImagesCat. No.: HY-N1289CAS No.: 864719-17-5Sequosempervirin B, a norlignan isolated from the branches and leaves of Sequoia sempervirens, has antifungal properties. Sequosempervirin B has an inhibitory effect on cyclic AMP phosphodiesterase.
-
ICI-170777
0 ImagesCat. No.: HY-19091CAS No.: 123297-52-9ICI-170777 is an orally active cardiotonic agent and type III Phosphodiesterase inhibitor, with an IC50 of 2.5 μM against cyclic AMP phosphodiesterase type III from canine cardiac fractions. ICI-170777 inhibits Aldrin epoxidase and pentobarbital metabolism. It enhances β-adrenergic receptor-mediated positive inotropic effects without causing chronotropic effects, while also exerting balanced arteriolar/venular vasodilator, platelet aggregation inhibitor and smooth muscle relaxant activities. ICI-170777 restores cardiac function in an acute canine heart failure model, exhibits additive effects when combined with Ouabain (HY-B1457), and shows no significant activity against multiple receptor classes or non-cardiac systems. ICI-170777 can be used in research related to congestive heart failure.
-
Amrinone lactate
0 ImagesCat. No.: HY-16256CAS No.: 75898-90-7Amrinone lactate is a positive inotropic-vasodilator agent. Amrinone lactate is a selective phosphodiesterase III inhibitor that increases cyclic adenosine monophosphate by preventing its breakdown. Amrinone lactate is also an orally active, non-glycosidic and non-catecholamine cardiotonic agent.
-
Girisopam
0 ImagesCat. No.: HY-187129CAS No.: 82230-53-3Girisopam is a PDE inhibitor with IC50 values of 3.2, 4.0, and 12.5 μM against PDE4, PDE2, and PDE5, respectively. Girisopam exhibits anxiolytic, antidepressant, anti-aggressive, and antipsychotic activities. The binding sites of Girisopam are enriched exclusively in the basal ganglia of rat brains, and depletion of these sites is associated with damage to the striatonigral pathway. Girisopam enhances the potency of μ-opioid receptor agonists, attenuates the antagonistic effect of low-dose Naloxone (HY-17417A), and synergistically potentiates the anti-fighting effect of Chlorpromazine (HY-12708). Girisopam can be used in studies related to psychiatric disorders such as anxiety and depression.
-
Ronomilast
0 ImagesCat. No.: HY-15179CAS No.: 418794-42-0Synonyms: Elbimilast; ELB353Ronomilast (Elbimilast; ELB353) is an orally active phosphodiesterase-4 (PDE4) inhibitor with an IC50 of 3 nM. Revamilast can be used for research to inflammation related diseases.
-
SAR156497
0 ImagesCat. No.: HY-12476CAS No.: 1256137-14-0SAR156497 (compound 47) is an Aurora inhibitor, with IC50 values of 0.6 nM and 1 nM for Aurora A and Aurora B, respectively. SAR156497 can also inhibit PDE3, with IC50 value of 4 μM. SAR156497 can be used in anticancer research.
-
PDE1-IN-11
0 ImagesPDE1-IN-11 (Compound 5cc) is an orally active and highly selective PDE1A1 inhibitor. PDE1-IN-11 increases intracellular cAMP and cGMP levels, activating the PKA-CREB and NO-cGMP-PKG signaling pathways, promoting osteoblast differentiation and bone formation, while suppressing osteoclastogenesis and bone resorption. PDE1-IN-11 is promising for research of postmenopausal osteoporosis (PMO) and other bone metabolism disorders.
-
PDE10-IN-6
0 ImagesCat. No.: HY-120684CAS No.: 1207549-69-6PDE10-IN-6 is a phosphodiesterase-10 inhibitor that inhibits the breakdown of cAMP and cGMP, thereby slowing or halting their hydrolysis.
-
Milrinone solution
0 ImagesCat. No.: HY-FL14252CAS No.: 78415-72-2Synonyms: Win 47203 solution
-
Vardenafil-d4
0 ImagesCat. No.: HY-B0442S1CAS No.: 2012598-83-1
-
BL-122
0 ImagesCat. No.: HY-114218CAS No.: 1220393-12-3BL-122 is a selective phosphodiesterase-5 (PDE-5) inhibitor. BL-122 can increase the level of cGMP in the tissue, promote the expression of nitric oxide (NO), and mediate the relaxation of smooth muscle. BL-122 can be used for the researches of inflammation, immunology and cardiovascular disease, such as asthma and hypertension.
-
Glaucine hydrobromide
0 ImagesCat. No.: HY-W726101CAS No.: 5996-06-5Synonyms: O,O-Dimethylisoboldine hydrobromide; S-(+)-Glaucine hydrobromide; NSC 34396 hydrobromideGlaucine hydrobromide (O,O-Dimethylisoboldine hydrobromide; S-(+)-Glaucine hydrobromide; NSC 34396 hydrobromide) is an alkaloid extracted from Glaucium flavum that possesses various activities, including cough relief, bronchodilation, anti-inflammatory effects, analgesia, antipyretic properties, and anticancer effects. Glaucine hydrobromide acts as a selective and orally active inhibitor of phosphodiesterase 4 (PDE4), with a Ki of 3.4 µM in human bronchial tissues and polymorphonuclear leukocytes. Glaucine hydrobromide induces relaxation of human isolated bronchi by antagonizing calcium channels. Additionally, Glaucine hydrobromide inhibits the activation of NF-κB, leading to a reduction in the expression of the MMP-9 gene, thereby suppressing the migration and invasion of breast cancer cells. Therefore, Glaucine hydrobromide holds potential for research in asthma and breast cancer.
-
UK 343664
0 ImagesCat. No.: HY-105341CAS No.: 215297-27-1UK 343664 is a potent, orally active and selective PDE5 inhibitor. UK 343664 partially reverses Thromboxane-induced pulmonary hypertension.
-
Carbazeran citrate
0 ImagesCat. No.: HY-108680CAS No.: 153473-94-0Carbazeran citrate is a phosphodiesterase inhibitor. Carbazeran citrate is oxidized by aldehyde oxidase/AOX1 to 4-oxo-Carbazeran citrate/hydroxyCarbazeran citrate, serving as an AOX1 probe and competitively inhibiting xanthine oxidase. Carbazeran citrate can be used in research on congestive heart failure and chronic heart failure.
-
ATX inhibitor 22
0 ImagesCat. No.: HY-149018CAS No.: 2969213-59-8
-
BC12
0 ImagesCat. No.: HY-119514CAS No.: 423744-89-2BC12 is a barbituric acid derivative and a phosphodiesterase 7 (PDE7) inhibitor, with an IC50 of 0.77 μM against human targets. BC12 inhibits the enzymatic activity of PDE7, but this activity is not the driver of its immunomodulatory effects on T lymphocytes. BC12 blocks the upregulation of IL-2 transcription in activated T cells. BC12 modulates the transcriptional response of T cells upon stimulation, exerting anti-inflammatory and pro-stress effects. BC12 inhibits the proliferation of primary mouse T cells and the IL-2 secretion of human peripheral blood T lymphocytes. BC12 exerts immunosuppressive and immunomodulatory effects on T lymphocyte function. BC12 can be used in research related to T lymphocyte-mediated diseases.
